Biotech Values

[Richter718]

<<<<What you’re calling “Survivorship Bias” I like to call program-survival bias so as to make it clear that it has nothing at all to do with patient survival >>>>

Perhaps caution of a similiar situation would apply to Genaera as it now stands. Is this your perception, obviously taking into account that we don't have even a multiple survival bias after one trial?